The chart of Ionis Pharmaceuticals doesn’t look like much but the fundamentals show eye-popping revenue growth.
Ablynx stock is a late-stage clinical development company that is finally going to bring a product to market in Germany in 2018.
Ampliphi Biosciences stock has rising large players volume after the company released incredible phase 1 trial results from their phage therapy cure for antibiotic resistant superbugs.
Immunomedics stock chart shows rising large players volume while the stock pulls back. This positive divergence suggests large players are buying on pullbacks.
Galapagos stock could be an attractive acquisition for Gilead, so as the rumors go.
Galectin Therapeutics stock is a completely technical play on an oversold chart setup. This is a quick swing move up gambit as the company reports Phase 2b top-line data.
Aeterna Zentaris stock is a short-term play on the PDUFA date of December 30, 2017. The gambit is that the company will get FDA approval of Macrilen.